This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Mohan BS, Nambiar V, et al., COVID-19: An Insight into SARS-CoV-2 Pandemic Originated at Wuhan City in Hubei Province of China. J Infect Dis Epidemiol, 2020 6:146. doi.org/10.23937/2474-3658/1510146MohanBSNambiarV, COVID-19: An Insight into SARS-CoV-2 Pandemic Originated at Wuhan City in Hubei Province of China. , 20206:146. doi.org/10.23937/2474-3658/1510146Open DOISearch in Google Scholar
Vargas M., Servillo G., Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review. European Review for Medical and Pharmacological Sciences, 2020. 24:p. 1.VargasM.ServilloG.Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review. , 2020. 24:p. 1.Search in Google Scholar
Cao, B., Wang, Y., A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl. J. Med. 2020, 382, 1787–1799., DOI : 10.1056/NEJMoa2001282CaoB.WangY.A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. . 2020, 382, 1787–1799., DOI : 10.1056/NEJMoa2001282Open DOISearch in Google Scholar
Wang, J. Fast identification of possible drug treatment of Coronavirus Disease-19 (COVID-19) through computational drug repurposing study. J. Chem. Inf. Model. 2020, 60, 3277–3286WangJ.Fast identification of possible drug treatment of Coronavirus Disease-19 (COVID-19) through computational drug repurposing study. . 2020, 60, 3277–3286Search in Google Scholar
Nutho, B., Mahalapbutr, P., Why are Lopinavir and Ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms. Biochemistry 2020, 59, 1769–1779.NuthoB.MahalapbutrP.Why are Lopinavir and Ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms. 2020, 59, 1769–1779.Search in Google Scholar
Yan D, Liu XY, Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalized non-critically ill patients with SARS-CoV-2 infection. Eur Respir J. 2020 Jul 16;56(1):2000799.YanDLiuXYFactors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalized non-critically ill patients with SARS-CoV-2 infection. . 2020Jul16;56(1):2000799.Search in Google Scholar
Lecronier M, Beurton A, Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: An opportunistic retrospective analysis. Crit Care 2020;24:418.LecronierMBeurtonAComparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: An opportunistic retrospective analysis. 2020;24:418.Search in Google Scholar
Kim JW, Kim EJ, Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019. Korean J Intern Med. 2020 Jun 16.KimJWKimEJLopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019. . 2020Jun16.Search in Google Scholar
Lee JE, Lee SO, et al. Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study. Antiviral Therapy. 2021;26(1-2):34–42. doi:10.1177/13596535211039394LeeJELeeSOComparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study. . 2021;26(1-2):34–42. doi:10.1177/13596535211039394Open DOISearch in Google Scholar
Arabi YM, Gordon AC, et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med. 2021;47(8):867–886. doi:10.1007/s00134-021-06448-5ArabiYMGordonACLopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. . 2021;47(8):867–886. doi:10.1007/s00134-021-06448-5Open DOISearch in Google Scholar
Yueping Li, Zhiwei Xie, Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial, Clinical Advances, 2020, 1.LiYuepingXieZhiweiEfficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial, , 2020, 1.Search in Google Scholar
Ye X.T., Luo Y.L, et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur. Rev. Med. Pharm. Sci. 2020, 24, 3390–3396.YeX.T.LuoY.LClinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. . 2020, 24, 3390–3396.Search in Google Scholar
Kocayiğit H, Özmen Süner K, et al. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19. J Clin Pharm Ther. 2021;46(2):454–459. doi:10.1111/jcpt.13305KocayiğitHÖzmen SünerKObservational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19. . 2021;46(2):454–459. doi:10.1111/jcpt.13305Open DOISearch in Google Scholar
Lowe DM, Brown LK, et al. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomized, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19. PLoS Med. 2022;19(10): e1004120. Published 2022 Oct 19. DOI: 10.1371/journal.pmed.1004120LoweDMBrownLKFavipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomized, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19. . 2022;19(10): e1004120. Published 2022 Oct 19. DOI: 10.1371/journal.pmed.1004120Open DOISearch in Google Scholar